D. Anderson, E. Maraskovsky, W. Billingsley, W. Dougall, M. Tometsko et al., A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, vol.272, issue.6656, pp.175-184, 1997.
DOI : 10.1074/jbc.272.40.25190

W. Boyle, W. Simonet, and D. Lacey, Osteoclast differentiation and activation, Nature, vol.20, issue.Suppl., pp.337-379, 2003.
DOI : 10.1007/s007740200049
URL : http://www.nature.com/nature/journal/v423/n6937/pdf/nature01658.pdf

W. Simonet, D. Lacey, C. Dunstan, M. Kelley, M. Chang et al., Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-328, 1997.
DOI : 10.1016/S0092-8674(00)80209-3

D. Jones, T. Nakashima, O. Sanchez, I. Kozieradzki, S. Komarova et al., Regulation of cancer cell migration and bone metastasis by RANKL, Nature, vol.17, issue.Suppl., pp.692-698, 2006.
DOI : 10.1023/A:1006689719505
URL : http://www.nature.com/nature/journal/v440/n7084/pdf/nature04524.pdf

D. Heymann, Y. Fortun, F. Rédini, and M. Padrines, Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools, Drug Discovery Today, vol.10, issue.4, pp.242-249, 2005.
DOI : 10.1016/S1359-6446(04)03265-9

J. Jules, J. Ashley, and X. Feng, Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis, Expert Opinion on Therapeutic Targets, vol.109, issue.12, pp.923-957, 2010.
DOI : 10.1007/s001980200061

B. Feeley, N. Liu, A. Conduah, L. Krenek, K. Roth et al., Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration, Journal of Bone and Mineral Research, vol.7, issue.Suppl, pp.1571-80, 2006.
DOI : 10.3816/CGC.2002.n.016
URL : http://onlinelibrary.wiley.com/doi/10.1359/jbmr.060706/pdf

F. Lamoureux, G. Picarda, J. Rousseau, C. Gourden, S. Battaglia et al., Therapeutic efficacy of soluble receptor activator of nuclear factor-??B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma, Molecular Cancer Therapeutics, vol.7, issue.10, pp.3389-98, 2008.
DOI : 10.1158/1535-7163.MCT-08-0497
URL : https://hal.archives-ouvertes.fr/inserm-00332021

J. Body, P. Greipp, R. Coleman, T. Facon, F. Geurs et al., A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases, Cancer, vol.14, issue.S3, pp.887-92, 2003.
DOI : 10.1002/cncr.11138

F. Lamoureux, G. Picarda, L. Garrigue-antar, M. Baud-'huin, V. Trichet et al., Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma, Cancer Research, vol.69, issue.2, pp.526-562, 2009.
DOI : 10.1158/0008-5472.CAN-08-2648

J. Rousseau, V. Escriou, F. Lamoureux, R. Brion, J. Chesneau et al., Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models, Journal of Bone and Mineral Research, vol.390, issue.10, pp.2452-62, 2011.
DOI : 10.1016/j.bbrc.2009.10.020
URL : http://onlinelibrary.wiley.com/doi/10.1002/jbmr.455/pdf

S. Cohen, R. Dore, N. Lane, P. Ory, C. Peterfy et al., Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, Arthritis & Rheumatism, vol.27, issue.5, pp.1299-309, 2008.
DOI : 10.1016/S0002-9440(10)64417-3

D. Heymann, Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences, Journal of Bone Oncology, vol.1, issue.1, pp.2-11, 2012.
DOI : 10.1016/j.jbo.2012.03.001
URL : https://hal.archives-ouvertes.fr/inserm-00719461

J. Xie, M. Namjoshi, E. Wu, K. Parikh, M. Diener et al., Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases, Journal of Managed Care Pharmacy, vol.17, issue.8, pp.621-664, 2011.
DOI : 10.18553/jmcp.2011.17.8.621

T. Wada, T. Nakashima, N. Hiroshi, and J. Penninger, RANKL???RANK signaling in osteoclastogenesis and bone disease, Trends in Molecular Medicine, vol.12, issue.1, pp.17-25, 2006.
DOI : 10.1016/j.molmed.2005.11.007

K. Aoki, H. Saito, C. Itzstein, M. Ishiguro, T. Shibata et al., A TNF receptor loop peptide mimic blocks RANK ligand???induced signaling, bone resorption, and bone loss, Journal of Clinical Investigation, vol.116, issue.6, pp.1525-1559, 2006.
DOI : 10.1172/JCI22513
URL : http://www.jci.org/articles/view/22513/files/pdf

A. Hasegawa, X. Cheng, K. Kajino, A. Berezov, K. Murata et al., Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism, Proceedings of the National Academy of Sciences, vol.10, issue.20, pp.6599-604, 2004.
DOI : 10.1038/sj.gt.3302067
URL : http://www.pnas.org/content/101/17/6599.full.pdf

C. Liu, T. Walter, P. Huang, S. Zhang, X. Zhu et al., Structural and Functional Insights of RANKL-RANK Interaction and Signaling, The Journal of Immunology, vol.184, issue.12, pp.6910-6929, 2010.
DOI : 10.4049/jimmunol.0904033
URL : http://www.jimmunol.org/content/jimmunol/184/12/6910.full.pdf

H. Ta, G. Nguyen, H. Jin, J. Choi, H. Park et al., Structure-based development of a receptor activator of nuclear factor-??B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis, Proceedings of the National Academy of Sciences, vol.277, issue.8, pp.20281-20287, 2010.
DOI : 10.1074/jbc.M106525200

K. Kajiwara, A. Saito, S. Ogata, and M. Tanihara, Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively, Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics, vol.1699, issue.1-2, pp.131-138, 2004.
DOI : 10.1016/S1570-9639(04)00052-4

S. Theoleyre, Y. Wittrant, S. Tat, Y. Fortun, F. Rédini et al., The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-75, 2004.
DOI : 10.1016/j.cytogfr.2004.06.004

S. Lien and H. Lowman, Therapeutic peptides, Trends in Biotechnology, vol.21, issue.12, pp.556-62, 2003.
DOI : 10.1016/j.tibtech.2003.10.005

B. Brooks, R. Bruccoleri, B. Olafson, D. States, S. Swaminathan et al., CHARMM: A program for macromolecular energy, minimization, and dynamics calculations, Journal of Computational Chemistry, vol.I, issue.2, pp.187-217, 1983.
DOI : 10.1145/321796.321811

G. Wu, D. Robertson, I. Clb, and M. Vieth, Detailed analysis of grid-based molecular docking: A case study of CDOCKER?A CHARMm-based MD docking algorithm, Journal of Computational Chemistry, vol.42, issue.13, pp.1549-62, 2003.
DOI : 10.1002/(SICI)1096-987X(19981115)19:14<1612::AID-JCC7>3.0.CO;2-M

M. Baudhuin, L. Duplomb, S. Teletchea, C. Charrier, M. Maillasson et al., Factor viii/von willebrand factor complex inhibits rankl-induced osteoclastogenesis and controls cell survival, Bone, vol.44, issue.46, pp.31704-31717, 2009.
DOI : 10.1016/j.bone.2009.03.639

D. States, R. Haberkorn, and D. Ruben, A two-dimensional nuclear overhauser experiment with pure absorption phase in four quadrants, Journal of Magnetic Resonance (1969), vol.48, issue.2, pp.286-92, 1982.
DOI : 10.1016/0022-2364(82)90279-7

M. Piotto, V. Saudek, and V. Sklenár, Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions, Journal of Biomolecular NMR, vol.87, issue.6, pp.661-666, 1992.
DOI : 10.1016/0022-2364(90)90082-K

T. Hwang and A. Shaka, Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients, Journal of Magnetic Resonance, Series A, vol.112, issue.2, pp.275-284, 1995.
DOI : 10.1006/jmra.1995.1047

A. Bax and D. Davis, MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy, Journal of Magnetic Resonance (1969), vol.65, issue.2, pp.355-60, 1985.
DOI : 10.1016/0022-2364(85)90018-6

Y. Xia, Q. Zhu, K. Jun, J. Wang, and X. Gao, Clean STD-NMR spectrum for improved detection of ligand-protein interactions at low concentration of protein, Magnetic Resonance in Chemistry, vol.277, issue.12, pp.918-942, 2010.
DOI : 10.1002/mrc.2687

B. Cutting, S. Shelke, Z. Dragic, B. Wagner, H. Gathje et al., Sensitivity enhancement in saturation transfer difference (STD) experiments through optimized excitation schemes, Magnetic Resonance in Chemistry, vol.3, issue.9, pp.720-724, 2007.
DOI : 10.1002/mrc.2033

M. Baud-'huin, R. R. Charrier, C. Riet, A. Moreau, A. Brion et al., Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis, The Journal of Pathology, vol.102, issue.1, pp.77-86, 2010.
DOI : 10.1016/S0002-9440(10)64556-7

A. Boyde, N. Ali, and S. Jones, Resorption of dentine by isolated osteoclasts in vitro, British Dental Journal, vol.156, issue.6, pp.216-220, 1984.
DOI : 10.1038/sj.bdj.4805313

M. Baud-'huin, C. Charrier, G. Bougras, R. Brion, F. Lezot et al., Proteoglycans and osteolysis, Methods Mol Biol, vol.836, pp.323-360, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00667515

M. Pfaffl, A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids Research, vol.29, issue.9, p.45, 2001.
DOI : 10.1093/nar/29.9.e45

J. Vandesompele, D. Preter, K. Pattyn, F. Poppe, B. Van-roy et al., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol, vol.3, issue.7, p.34, 2002.

A. Parfitt, M. Drezner, F. Glorieux, J. Kanis, H. Malluche et al., Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee, Journal of Bone and Mineral Research, vol.10, issue.6, pp.595-610, 1987.
DOI : 10.7326/0003-4819-106-1-114

D. Heymann, B. Ory, F. Blanchard, M. Heymann, P. Coipeau et al., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.
DOI : 10.1016/j.bone.2005.02.020

F. Lamoureux, G. Picarda, L. Garrigue-antar, M. Baud-'huin, V. Trichet et al., Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma, Cancer Research, vol.69, issue.2, pp.526-562, 2009.
DOI : 10.1158/0008-5472.CAN-08-2648

S. Edelstein, L. Novère, and N. , Cooperativity of Allosteric Receptors, Journal of Molecular Biology, vol.425, issue.9, pp.1424-1456, 2013.
DOI : 10.1016/j.jmb.2013.03.011
URL : https://doi.org/10.1016/j.jmb.2013.03.011

K. Mori, L. Goff, B. Charrier, C. Battaglia, S. Heymann et al., DU145 human prostate cancer cells express functional receptor activator of NF??B: New insights in the prostate cancer bone metastasis process, Bone, vol.40, issue.4, pp.981-90, 2007.
DOI : 10.1016/j.bone.2006.11.006

S. Cenci, M. Weitzmann, C. Roggia, N. Namba, D. Novack et al., Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-??, Journal of Clinical Investigation, vol.106, issue.10, pp.1229-1266, 2000.
DOI : 10.1172/JCI11066
URL : http://www.jci.org/articles/view/11066/files/pdf

C. Roggia, Y. Gao, S. Cenci, M. Weitzmann, G. Toraldo et al., Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo, Proceedings of the National Academy of Sciences, vol.20, issue.3, pp.13960-13965, 2001.
DOI : 10.1016/S8756-3282(96)00384-5

D. Heath, K. Vanderkerken, X. Cheng, O. Gallagher, M. Prideaux et al., An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma, Cancer Research, vol.67, issue.1, pp.202-210, 2007.
DOI : 10.1158/0008-5472.CAN-06-1287
URL : http://cancerres.aacrjournals.org/content/canres/67/1/202.full.pdf

J. Pons, V. Tanchou, J. Girault, G. Bertho, and N. Evrard-todeschi, NMR Applications for Identifying &#946;-TrCP Protein-Ligand Interactions, Mini-Reviews in Medicinal Chemistry, vol.11, issue.4, pp.283-97, 2011.
DOI : 10.2174/138955711795305344

A. Kumar, G. Wagner, R. Ernst, and K. Wuethrich, Buildup rates of the nuclear Overhauser effect measured by two-dimensional proton magnetic resonance spectroscopy: implications for studies of protein conformation, Journal of the American Chemical Society, vol.103, issue.13, pp.3654-3662, 1981.
DOI : 10.1021/ja00403a008

D. Heymann, B. Ory, F. Gouin, J. Green, and F. Rédini, Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-380, 2004.
DOI : 10.1016/j.molmed.2004.05.007

V. Stresing, F. Daubiné, I. Benzaid, H. Mönkkönen, and P. Clézardin, Bisphosphonates in cancer therapy, Cancer Letters, vol.257, issue.1, pp.16-35, 2007.
DOI : 10.1016/j.canlet.2007.07.007

P. Kostenuik, H. Nguyen, J. Mccabe, K. Warmington, C. Kurahara et al., Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*, Journal of Bone and Mineral Research, vol.24, issue.2, pp.182-95, 2009.
DOI : 10.1359/jbmr.081112

W. Takasaki, Y. Kajino, K. Kajino, R. Murali, and M. Greene, Structure???based design and characterization of exocyclic peptidomimetics that inhibit TNF?? binding to its receptor, Nature Biotechnology, vol.112, issue.12, pp.1266-70, 1997.
DOI : 10.1074/jbc.270.33.19509

P. Vanhee, F. Stricher, L. Baeten, E. Verschueren, T. Lenaerts et al., Protein-Peptide Interactions Adopt the Same Structural Motifs as Monomeric Protein Folds, Structure, vol.17, issue.8, pp.1128-1164, 2009.
DOI : 10.1016/j.str.2009.06.013
URL : https://doi.org/10.1016/j.str.2009.06.013

S. Fleishman, T. Whitehead, E. Strauch, J. Corn, S. Qin et al., Community-Wide Assessment of Protein-Interface Modeling Suggests Improvements to Design Methodology, Journal of Molecular Biology, vol.414, issue.2, pp.289-302, 2011.
DOI : 10.1016/j.jmb.2011.09.031
URL : https://hal.archives-ouvertes.fr/inria-00637848

V. Duheron, E. Hess, M. Duval, M. Decossas, B. Castaneda et al., Receptor activator of NF-??B (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit, Proceedings of the National Academy of Sciences, vol.99, issue.13, pp.5342-5349, 2011.
DOI : 10.1073/pnas.132636999
URL : https://hal.archives-ouvertes.fr/hal-00579674

K. Bleicher, H. Böhm, K. Müller, and A. Alanine, A guide to drug discovery: Hit and lead generation: beyond high-throughput screening, Nature Reviews Drug Discovery, vol.2, issue.5, pp.369-78, 2003.
DOI : 10.1038/nrd1086

A. Pangrazio, B. Cassani, M. Guerrini, J. Crockett, V. Marrella et al., RANK-dependent autosomal recessive osteopetrosis: Characterization of five new cases with novel mutations, Journal of Bone and Mineral Research, vol.28, issue.2, pp.342-51, 2012.
DOI : 10.1002/humu.20394

M. Guerrini, C. Sobacchi, B. Cassani, M. Abinun, S. Kilic et al., Human Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations, The American Journal of Human Genetics, vol.83, issue.1, pp.64-76, 2008.
DOI : 10.1016/j.ajhg.2008.06.015
URL : https://doi.org/10.1016/j.ajhg.2008.06.015

S. Sherry, M. Ward, M. Kholodov, J. Baker, L. Phan et al., dbSNP: the NCBI database of genetic variation, Nucleic Acids Research, vol.29, issue.1, pp.308-319, 2001.
DOI : 10.1093/nar/29.1.308

P. Weinkam, Y. Chen, J. Pons, and A. Sali, Impact of Mutations on the Allosteric Conformational Equilibrium, Journal of Molecular Biology, vol.425, issue.3, pp.647-61, 2013.
DOI : 10.1016/j.jmb.2012.11.041

J. Naismith and S. Sprang, Modularity in the TNF-receptor family, Trends in Biochemical Sciences, vol.23, issue.2, pp.74-83, 1998.
DOI : 10.1016/S0968-0004(97)01164-X

D. Mcgregor, Discovering and improving novel peptide therapeutics, Current Opinion in Pharmacology, vol.8, issue.5, pp.616-625, 2008.
DOI : 10.1016/j.coph.2008.06.002

K. Aoki, N. Alles, N. Soysa, and K. Ohya, Peptide-based delivery to bone, Advanced Drug Delivery Reviews, vol.64, issue.12, pp.1220-1258, 2012.
DOI : 10.1016/j.addr.2012.05.017